RankAlpha logo
Back to Rankings

DNTH

Dianthus TherapeuticsD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
View Chart
Current thesis
Primary sources show multiple shots on goal around claseprubart: early CAPTIVATE GO language in CIDP, a planned gMG Phase 3 start in mid-2026, and MMN data in 2H 2026, while March 2026 FDA feedback reduced a visible screening/safety-framing overhang across trials [#10-K-2026-03-09] [#8-K-2026-03-26].
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +6.2.
What can break
Clinical readouts remain binary and can overwhelm favorable operational updates.
Momentum
80
Value
41
Sentiment
24
Setup hits (3d)
— · Net —
AI TargetsBase $82.00 · Bull $115.00 · Bear $55.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net —
Target $128.69
Why
Momentum80 · Δ7d +6.2
Value41 · Δ7d -0.1
Sentiment24 · Δ7d -8.6
So what
Weak posture. Prioritize risk control and patience.
Setup hits not loaded

Load setup hits to see net bias and recent triggers.

Load setup hits
Lead driver: Momentum · See technicals
Momentum
80
26% active weight
Current posture
7d trendImproving
Δ7d
+6.2
Δ21d
+0.5
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
24
34% active weight
Current posture
7d trendSoftening
Δ7d
-8.6
Δ21d
-9.7
Why this grade

Composite grade D. Momentum 80.3 / Value 41.1 / Sentiment 24.3

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$5.77B
Beta
1.59
Shares Out
54.67M
P/E (TTM) · Derived
-25.1
P/S (TTM)
513.87
P/FCF (TTM) · Derived
-33.79
Rev YoY
-60.2%
EPS YoY
+3.1%
Gross Margin
+72.2%
Op Margin
-4558.4%
Net Debt
-$402.91M
Current Ratio
29.25
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology